However, tumor mice with a heterozygous deletion of Smarca5 did not show a significantly prolonged survival as compared to control tumor mice, while mice with a homozygous Smarca5 deletion displayed a significant survival benefit (Fig. 2g). Here, SMARCA5 is linked to neoplasm.